Neha Krishnamohan - 07 Jun 2021 Form 4 Insider Report for Kinnate Biopharma Inc.

Role
Chief Financial Officer
Signature
/s/ Mark A. Meltz, attorney-in-fact
Issuer symbol
N/A
Transactions as of
07 Jun 2021
Net transactions value
$0
Form type
4
Filing time
08 Jun 2021, 20:32:03 UTC
Next filing
15 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNTE Employee Stock Option (right to buy) Award $0 +270,000 $0.000000 270,000 07 Jun 2021 Common Stock 270,000 $23.26 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4th of the shares underlying the Option shall vest and become exercisable one year from the date of grant (the "Vest Base Date"), and 1/36th of the remaining shares subject to the Option shall vest thereafter on the same day of the month as the Vest Base Date.